Fluoxetine and Raynaud's phenomenon: friend or foe? - Test2 - elhamkhani - TriplyDB

Fluoxetine and Raynaud's phenomenon: friend or foe?

Fluoxetine and Raynaud's phenomenon: friend or foe?

http://www.wikidata.org/entity/Q48330196

about

Fluoxetine and Raynaud's phenomenon: friend or foe?

http://www.wikidata.org/entity/Q48330196

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Fluoxetine and Raynaud's phenomenon: friend or foe?

@en

Fluoxetine and Raynaud's phenomenon: friend or foe?

@nl

type

label

Fluoxetine and Raynaud's phenomenon: friend or foe?

@en

Fluoxetine and Raynaud's phenomenon: friend or foe?

@nl

prefLabel

Fluoxetine and Raynaud's phenomenon: friend or foe?

@en

Fluoxetine and Raynaud's phenomenon: friend or foe?

@nl

P1433

Q48330196-37CB172C-DA20-4474-9B52-ED2B1209517E

P1476

Q48330196-B9603B4A-B1CE-427F-A396-243651906B44

P2093

Q48330196-5A591E37-9826-44AD-8CDC-390904795FEA

Q48330196-B1363C1B-A80E-40BA-80D0-6BC65E2A09B4

P2860

Q48330196-174081D3-6FB3-4444-86A7-E014AE8C36B2

Q48330196-2D240CE0-8944-4ED1-91C2-EF967DC1CF62

Q48330196-3BD01317-76F4-4166-A69A-3F80F35F683E

Q48330196-3DEBD74E-AFBC-4AFC-8604-6E5F573430E3

Q48330196-44EAFB2F-7677-42E3-BEF0-25C7DB872436

Q48330196-64F1F7DD-01FD-45D0-BF77-F2C224A7DC90

Q48330196-7E75614C-9ABD-445C-A12C-66842D216491

Q48330196-AF5248CC-028C-485D-BC46-559237D1AC3B

Q48330196-B59768BC-6B7E-492D-94B4-D3D20B910595

Q48330196-C56D8D61-7579-4618-B071-225B496EE979

P304

Q48330196-14FC583A-AD5B-48A1-8F5C-FBA44E087AED

P31

Q48330196-10A031B2-CEA0-47D9-A7E4-BF5DED459E52

P356

Q48330196-D56CA17A-8E85-4771-8476-CC4FFFEAA16D

P407

Q48330196-30CD465C-F554-497B-AD2E-B8FC28D71B6B

P433

Q48330196-5D880E5B-9584-4F49-BC75-FF5F52828FA6

P478

Q48330196-B4F314C4-5DA0-44C7-8062-F87A9E87907B

P50

Q48330196-09B7C9F8-490E-44E7-B9B0-A6AA3D83E7B8

Q48330196-6E27A8A4-EDD8-49D2-BCE8-D9BC09C63CD9

Q48330196-E8AF269C-4B93-441E-883B-BCB1B222D9F2

P577

Q48330196-E1C1DE5A-32BD-4298-B987-D91BD4B05985

P698

Q48330196-CD6D4A46-0AFE-433E-A1BF-DA3192D9524B

P932

Q48330196-8604C771-41EA-44D5-B5E0-9EC8B6424EB5

P356

P1433

British Journal of Clinical Pharmacology

P1476

Fluoxetine and Raynaud's phenomenon: friend or foe?

@en

P2093

Marion Lepelley

http://www.w3.org/2001/XMLSchema#string

Thomas Gailland

http://www.w3.org/2001/XMLSchema#string

P2860

The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors

The Concise Guide to PHARMACOLOGY 2015/16: Enzymes

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

The Concise Guide to PHARMACOLOGY 2015/16: Voltage-gated ion channels.

Fluoxetine induces vasodilatation of cerebral arterioles by co-modulating NO/muscarinic signalling

Serotonin and blood pressure regulation.

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics

The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis.

Update of EULAR recommendations for the treatment of systemic sclerosis.

Adrenergic stimulation-released 5-HT stored in adrenergic nerves inhibits CGRPergic nerve-mediated vasodilatation in rat mesenteric resistance arteries.

P304

2307-2309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.13314

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P50

Matthieu Roustit

Jean-Luc Cracowski

P577

2017-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28580711

http://www.w3.org/2001/XMLSchema#string

P932

5595930

http://www.w3.org/2001/XMLSchema#string